Clinical Cancer Research, Vol 4, Issue 7 1649-1659, Copyright © 1998 by American Association for Cancer Research

ARTICLES

p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus

SC Anderson, DE Johnson, MP Harris, H Engler, W Hancock, WM Huang, KN Wills, RJ Gregory, S Sutjipto, SF Wen, S Lofgren, HM Shepard and DC Maneval
Canji Inc., San Diego, California 92121, USA.

p53 tumor suppressor gene therapy has been proposed for cancers characterized by inactivation of p53 function, and successful therapy will require efficient strategies for gene delivery. To maximize transgene expression in tumors, a clinical strategy has been proposed to treat neoplasms in the liver via hepatic artery administration of a recombinant adenovirus encoding wild-type p53 (rAd-p53). We have developed a syngeneic rat model using a p53mut hepatocellular carcinoma cell line (McA-RH7777) that results in multifocal liver tumor nodules to provide experimental support for this strategy. Treatment of McA-RH7777 cells with rAd-p53 in vitro resulted in efficient transgene expression, growth suppression, and apoptosis. Intrahepatic artery dosing with rAd-p53 or an adenovirus encoding beta-galactosidase (rAd-betagal) increased transgene expression in tumor tissue and decreased systemic exposure when compared with i.v. dosing. Daily hepatic artery dosing of rAd-p53 suppressed tumor growth when compared with untreated rats or animals treated with rAd-betagal. These data demonstrate the potential for arterial gene delivery to tumors using recombinant adenoviruses, and support continued investigation of rAd-p53 gene therapy for liver malignancies.

This article has been cited by other articles:

				T. Wirth, F. Kuhnel, B. Fleischmann-Mundt, N. Woller, M. Djojosubroto, K. L. Rudolph, M. Manns, L. Zender, and S. Kubicka Telomerase-Dependent Virotherapy Overcomes Resistance of Hepatocellular Carcinomas against Chemotherapy and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand by Elimination of Mcl-1 Cancer Res., August 15, 2005; 65(16): 7393 - 7402. [Abstract] [Full Text] [PDF]

				M E Guicciardi and G J Gores Apoptosis: a mechanism of acute and chronic liver injury Gut, July 1, 2005; 54(7): 1024 - 1033. [Full Text] [PDF]

				Z. F. Yang, D. W. Ho, C. T. Lam, J. M. Luk, C. T. Lum, W. C. Yu, R. T. Poon, and S. T. Fan Identification of Brain-Derived Neurotrophic Factor as a Novel Functional Protein in Hepatocellular Carcinoma Cancer Res., January 1, 2005; 65(1): 219 - 225. [Abstract] [Full Text] [PDF]

				L. L. Nielsen, M. Gurnani, B. Shi, G. Terracina, R. C. Johnson, J. Carroll, J. M. Mathis, and G. Hajian Derivation and Initial Characterization of a Mouse Mammary Tumor Cell Line Carrying the Polyomavirus Middle T Antigen: Utility in the Development of Novel Cancer Therapeutics Cancer Res., December 1, 2000; 60(24): 7066 - 7074. [Abstract] [Full Text]

				W. C. Russell Update on adenovirus and its vectors J. Gen. Virol., November 1, 2000; 81(11): 2573 - 2604. [Full Text]

				K. Ikeda, H. Wakimoto, T. Ichikawa, S. Jhung, F. H. Hochberg, D. N. Louis, and E. A. Chiocca Complement Depletion Facilitates the Infection of Multiple Brain Tumors by an Intravascular, Replication-Conditional Herpes Simplex Virus Mutant J. Virol., May 15, 2000; 74(10): 4765 - 4775. [Abstract] [Full Text]

				R. Gerolami, J. Cardoso, M. Lewin, M.-P. Bralet, A. SaCunha, O. Clément, C. Bréchot, and P.-L. Tran Evaluation of HSV-tk Gene Therapy in a Rat Model of Chemically Induced Hepatocellular Carcinoma by Intratumoral and Intrahepatic Artery Routes Cancer Res., February 1, 2000; 60(4): 993 - 1001. [Abstract] [Full Text]

				L. L. Nielsen, B. Shi, G. Hajian, B. Yaremko, P. Lipari, E. Ferrari, M. Gurnani, M. Malkowski, J. Chen, W. R. Bishop, et al. Combination Therapy with the Farnesyl Protein Transferase Inhibitor SCH66336 and SCH58500 (p53 Adenovirus) in Preclinical Cancer Models Cancer Res., December 1, 1999; 59(23): 5896 - 5901. [Abstract] [Full Text] [PDF]